Next-Generation ADPR-Based Therapeutics and Diagnostics
Legal Citation
Summary of the Inventive Concept
This inventive concept envisions a paradigm shift in ADPR-based treatments, leveraging advanced technologies such as nanoparticle vectors, machine learning algorithms, and wearable devices to revolutionize the prevention, diagnosis, and treatment of adenovirus-related diseases and conditions.
Background and Problem Solved
The original patent disclosed methods for using ADPR to treat various diseases and conditions. However, these methods have limitations, including lack of targeted delivery, limited dosing precision, and inadequate monitoring capabilities. The present inventive concept addresses these limitations by introducing novel systems, methods, and devices that overcome these challenges.
Detailed Description of the Inventive Concept
The inventive concept comprises a suite of innovative solutions, including nanoparticle vectors for targeted delivery of ADPR-based therapeutics, machine learning algorithms for personalized treatment and optimal dosing, wearable devices for real-time monitoring and automated dosing adjustments, computer-implemented systems for simulating treatment outcomes and predicting optimal therapeutic strategies, and mRNA-based vaccines for generating ADPR-based vaccines. These solutions work in concert to provide a comprehensive approach to ADPR-based treatments, enabling more effective prevention, diagnosis, and treatment of adenovirus-related diseases and conditions.
Novelty and Inventive Step
The inventive concept's novelty lies in its integration of advanced technologies to create a next-generation ADPR-based treatment paradigm. The inventive step resides in the specific combination and implementation of these technologies, which overcome the limitations of the original patent and provide a significant improvement in ADPR-based treatments.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different nanoparticle materials, varying machine learning algorithms, or alternative wearable device designs. Variations could also include the application of the inventive concept to other disease areas or conditions, such as cancer or inflammatory disorders.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in the prevention, diagnosis, and treatment of adenovirus-related diseases and conditions. The target market includes pharmaceutical companies, biotechnology firms, and healthcare providers seeking to improve treatment outcomes and patient care.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, with a focus on targeted drug delivery, personalized medicine, and advanced therapeutic technologies involving nucleotide-based treatments
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in biotechnology, pharmaceutical sciences, or biomedical engineering, possessing expertise in drug delivery systems, machine learning applications in medicine, and molecular therapeutics
Obviousness Rationale
A PHOSITA would recognize that the PTD represents a predictable extension of the source patent's ADPR-based therapeutic approach by applying known technological advancements in drug delivery, personalized medicine, and diagnostic technologies. The integration of nanoparticle vectors, machine learning, and wearable devices represents a logical progression of existing therapeutic strategies. The variations demonstrate standard technological improvements that would be apparent to a skilled practitioner seeking to enhance the efficacy and precision of ADPR-based treatments.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,561 |
|---|---|
| Title | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) |
| Assignee(s) | Invirsa, Inc. |